Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

Not Recruiting

Trial ID: NCT04508725


To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment

Official Title

Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

Stanford Investigator(s)

Alice C. Fan
Alice C. Fan

Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology

Ali Raza Khaki, MD
Ali Raza Khaki, MD

Clinical Assistant Professor, Medicine - Oncology

Aya Kamaya, MD
Aya Kamaya, MD

Professor of Radiology (Body Imaging)


Inclusion Criteria:

   - 18 years of age or older

   - Pathology-confirmed diagnosis of metastatic RCC

   - At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound

   - Written informed consent.

Specific inclusion criteria:

   - arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor
   (TKI) plus immune checkpoint inhibitor (ICI)

   - arm 2: planned to be treated with non-ICI therapy

Exclusion Criteria:

-Any comorbid condition that, in the opinion of the treating provider or the Protocol
Directors, compromises the participant's ability to participate in the study


diagnostic test: Doppler Ultrasound

device: Vantage 256 with C5-2v transducer

drug: Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor

other: non-ICI therapy

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christian Hoerner, PhD

New Trial Alerts

Receive email alerts when trials open to patients.